AJNR Am J Neuroradiol

1. KEEGAN BM, Messina SA, Hanson D, Holmes D, et al
   MR Imaging Features of Critical Spinal Demyelinating Lesions Associated with Progressive Motor Impairment.
   AJNR Am J Neuroradiol. 2024;45:943-950.
   

   >> Share

   
   

   
   Ann Neurol

2. HU Y, Frisell T, Alping P, Song H, et al
   Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
   Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
   

   >> Share

   
   
3. GRUT V, Bistrom M, Salzer J, Stridh P, et al
   Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
   Ann Neurol. 2024;96:302-305.
   

   >> Share

   
   

   
   J Neurol

4. VITI V, Zanetta C, Capra R, Municchi A, et al
   Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
   J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
   

   >> Share

   
   
5. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
   Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
   J Neurol. 2024;271:4599-4609.
   

   >> Share

   
   
6. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
   Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
   J Neurol. 2024;271:4495-4502.
   

   >> Share

   
   
7. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
   ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
   J Neurol. 2024;271:4348-4360.
   

   >> Share

   
   
8. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
   The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
   J Neurol. 2024;271:4019-4027.
   

   >> Share

   
   

   
   J Neurol Sci

9. TOOROP AA, Wessels MHJ, Gelissen LMY, Hoitsma E, et al
   Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
   J Neurol Sci. 2024;462:123102.
   

   >> Share

   
   

   
   Rev Neurol

10. FERNANDEZ O, Montalban X, Aguera E, Aladro Y, et al
    [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].
    Rev Neurol. 2024;79:51-66.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share